SpringWorks Therapeutics, Inc., a biopharmaceutical company specializing in severe rare diseases and cancer, announced that their management will participate in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas on May 14, 2024. The webcast of the chat can be accessed on the company’s website and a replay will be available for a limited time after the event.
SpringWorks Therapeutics is dedicated to developing life-changing medicines for individuals with severe rare diseases and cancer using a precision medicine approach. With a diversified targeted oncology pipeline, the company is conducting clinical trials in rare tumor types and genetically defined cancers. Their FDA-approved therapy, OGSIVEO®, is used to treat adult patients with desmoid tumors.
Founded in 2017, SpringWorks Therapeutics has rapidly progressed their lead product candidates into late-stage trials and has established collaborations with industry innovators and academia. This strategic approach, combined with operational excellence, has allowed them to create more solutions for cancer patients and unlock the full potential of their portfolio.
SpringWorks Therapeutics is focused on creating innovative treatments for rare diseases that have limited treatment options. They are committed to improving outcomes for patients by using advanced technologies and data analytics to identify new targets and develop personalized therapies. Their mission is to make life-changing medicines accessible to those who need them most, regardless of where they live or how much they can afford.
For more information about SpringWorks Therapeutics, visit their website and follow them on social media platforms. Contact Kim Diamond, Vice President of Communications and Investor Relations